262 related articles for article (PubMed ID: 16773184)
1. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
[TBL] [Abstract][Full Text] [Related]
2. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
3. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
4. MUC1 expression in human prostate cancer cell lines and primary tumors.
O'Connor JC; Julian J; Lim SD; Carson DD
Prostate Cancer Prostatic Dis; 2005; 8(1):36-44. PubMed ID: 15477874
[TBL] [Abstract][Full Text] [Related]
5. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product.
Burchell J; Taylor-Papadimitriou J
Epithelial Cell Biol; 1993 Oct; 2(4):155-62. PubMed ID: 7505698
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas.
Singh AP; Chauhan SC; Bafna S; Johansson SL; Smith LM; Moniaux N; Lin MF; Batra SK
Prostate; 2006 Mar; 66(4):421-9. PubMed ID: 16302265
[TBL] [Abstract][Full Text] [Related]
7. Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study.
Croce MV; Colussi AG; Price MR; Segal-Eiras A
Anticancer Res; 1997; 17(6D):4287-92. PubMed ID: 9494522
[TBL] [Abstract][Full Text] [Related]
8. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
[TBL] [Abstract][Full Text] [Related]
9. Second generation anti-MUC1 peptide monoclonal antibodies.
Xing PX; Prenzoska J; Quelch K; McKenzie IF
Cancer Res; 1992 Apr; 52(8):2310-7. PubMed ID: 1373108
[TBL] [Abstract][Full Text] [Related]
10. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer.
Peterson JA; Couto JR; Taylor MR; Ceriani RL
Cancer Res; 1995 Dec; 55(23 Suppl):5847s-5851s. PubMed ID: 7493358
[TBL] [Abstract][Full Text] [Related]
11. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.
Papadopoulos I; Sivridis E; Giatromanolaki A; Koukourakis MI
Clin Cancer Res; 2001 Jun; 7(6):1533-8. PubMed ID: 11410487
[TBL] [Abstract][Full Text] [Related]
13. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
14. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
15. MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage.
Kirschenbaum A; Itzkowitz SH; Wang JP; Yao S; Eliashvili M; Levine AC
Mol Urol; 1999; 3(3):163-168. PubMed ID: 10851319
[TBL] [Abstract][Full Text] [Related]
16. Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
Zhang S; Zhang HS; Cordon-Cardo C; Ragupathi G; Livingston PO
Clin Cancer Res; 1998 Nov; 4(11):2669-76. PubMed ID: 9829729
[TBL] [Abstract][Full Text] [Related]
17. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
18. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
19. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies against partially deglycosylated colon cancer mucin that recognize Tn antigen.
Huang J; Byrd JC; Siddiki B; Yuan M; Lau E; Kim YS
Dis Markers; 1992; 10(2):81-94. PubMed ID: 1281060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
